CN Patent

CN107759600A — 作为jak抑制剂的吡咯并嘧啶化合物的结晶

Assigned to Capital Pharmaceutical Holdings (beijing) Co Ltd · Expires 2018-03-06 · 8y expired

What this patent protects

本申请属于药物合成领域，具体而言，本申请涉及作为JAK抑制剂的吡咯并嘧啶化合物(式I)的结晶，还涉及结晶的制备方法、包含该结晶的结晶组合物、包含该结晶或其结晶组合物的药物组合物以及它们的医药用途。本申请的结晶具有纯度高、结晶度高、稳定性好等优点。

USPTO Abstract

本申请属于药物合成领域，具体而言，本申请涉及作为JAK抑制剂的吡咯并嘧啶化合物(式I)的结晶，还涉及结晶的制备方法、包含该结晶的结晶组合物、包含该结晶或其结晶组合物的药物组合物以及它们的医药用途。本申请的结晶具有纯度高、结晶度高、稳定性好等优点。

Drugs covered by this patent

Patent Metadata

Patent number
CN107759600A
Jurisdiction
CN
Classification
—
Expires
2018-03-06
Drug substance claim
No
Drug product claim
No
Assignee
Capital Pharmaceutical Holdings (beijing) Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.